Currently in Phase 3 clinical trials for AD dementia, small molecule drug candidate simufilam was hypothesized to suppress elevated mTOR activation in AD because it disrupts a predominant AD pathogenic pathway, and because it improves insulin receptor signaling (Wang et al., 2012; Wang et al., 2017). The gene discussed is INSR; the disease is Alzheimer disease.